earthbound

Historic mission from Houston space tech company plans for splashdown

Ax-1 is headed back to Earth after 12 days of research on the ISS. Photo courtesy of SpaceX

Editor's note: Undocking was delayed again on April 19, and a new timeline has not been announced. The original story is below.

After spending 12 days in space, a historic commercial space mission will splash back down on Earth this week.

Houston-based Axiom Space’s first mission Axiom mission 1 (Ax-1), which took off April 8 and connected to the International Space Station, has announced its plans for undocking and splashdown.

After some initial bad weather postponed the process, the four-member private astronaut crew now is aiming to undock at about 9 pm tonight, April 19, and then land off the coast of Florida at around 2:24 pm tomorrow, April 20. Just like launch, the coverage of both events will be available at Axiom's website.

The mission on SpaceX’s spacecraft sent four multinational private astronauts — Commander Michael López-Alegría, Pilot Larry Connor, Mission Specialist Eytan Stibbe, and Mission Specialist Mark Pathy — to the ISS to conduct research and familiarize Axiom with launch, docking, and more.

Axiom Space, which reached $1 billion valuation and joined the Houston unicorn club last year after a $130 million investment round, is working on the first commercial space station to replace the ISS. The first launch of that mission is expected in late 2024. In the meantime, Axiom has a series of commercial launches to the existing station currently in orbit in order to prepare for development and orchestration of Axiom Station.

The Ax-1 mission, which has provided daily updates, has conducted over 20 research projects and even hit a few milestones, including:

  • The first-ever music duet performance in space — Commander López-Alegría and Neo-Classical Piano Prodigy BLKBOK made music and space history with their piano and keyboard duet
  • The Aging and Heart Health investigation, an experiment from the Mayo Clinic — a study that analyzes human cells for genetic markers of cellular aging and explores cardiac-like cells' adaptation to microgravity
  • Observation of Transient Luminous Events — Specialist Stibbe completed a space observation experiment and photographed a lightning storm over Darwin, Australia, to enhance understanding of the electrical processes in the atmosphere and to determine whether there’s a connection with climate change
  • Testing of the Holoportation system — Mission Specialist Pathy set up two-way AI technology that will allow the ability of future crew members to explore deep space with the ability to virtually bring friends, family, and physicians close with them so that they can get an on-Earth experience
  • Several outreach calls to Earth to STEM students from around the world — this included a call to children at Space Center Houston

Axiom shares more details on its mission research projects — which span technologies such as future space habitats, cancer research, and devices to purify air on space stations — online.

“As the first step on a path to building a diverse, thriving economy in low-Earth orbit, Axiom has partnered with leaders in academia and industry to bring new users and new investigations in research to the space station,” says Christian Maender, director of In-space Manufacturing and Research for Axiom Space, in a news release. “The collection of biological and technological tests during the Ax-1 mission represent a breadth of research that will inform everything from human health considerations to novel infrastructure and design for our future homes away from Earth, beginning with Axiom Station.”

The four-person crew spent 12 days on the ISS. Photo courtesy of NASA

Trending News

Building Houston

 
 

You can now hop online and invest in this promising cell therapy startup. Photo via Getty Images

A clinical-stage company headquartered in Houston has opened an online funding campaign.

FibroBiologics, which is developing fibroblast cell-based therapeutics for chronic diseases, launched a campaign with equity crowdfunding platform StartEngine. The platform lets anyone — regardless of their net worth or income level — to invest in securities issued by startups.

The funding, according to a press release, will be used to support ongoing operations of Fibrobiologics and advance its clinical programs in multiple sclerosis, degenerative disc disease, wound care, extension of life, and cancer.

"We're excited to partner with StartEngine on this campaign. StartEngine has over 600,000 investors as part of their community and has raised over half a billion dollars for its clients," says FibroBiologics' Founder and CEO Pete O'Heeron, in the release.

"This is an exciting time at FibroBiologics as we continue progressing our clinical pipeline and developing innovative therapies to treat chronic diseases," he continues. "This new funding will fuel our growth in the lab and bring us one step closer to commercialization."

The campaign, launched this week, already has over 100 investors, at the time of publication, and has raised nearly $2 million, according to the page. The minimum investment is set at around $500, and the company's indicated valuation is $252.57 million.

In 2021, FibroBiologics announced its intention of going public. Last year, O'Heeron told InnovationMap on the Houston Innovators Podcast of the company's growth plans as well as the specifics of the technology.

Only two types of cells — stem cells and fibroblasts — can be used in cell therapy for a regenerative treatment, which is when specialists take healthy cells from a patient and inject them into a part of the body that needs it the most. As O'Heeron explains in the podcast, fibroblasts can do it more effectively and cheaper than stem cells.

"(Fibroblasts) can essentially do everything a stem cell can do, only they can do it better," says O'Heeron. "We've done tests in the lab and we've seen them outperform stem cells by a low of 50 percent to a high of about 220 percent on different disease paths."


Trending News